Garetosmab for FOP: Analyzing Its Potential in Bone Disease

Garetosmab is among the most promising experimental treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder in which soft tissues progressively turn to bone. In a phase 2 trial, the drug cut the formation of new bone lesions by roughly 90% compared to placebo, and it halved the proportion of patients experiencing the painful inflammatory episodes, called flare-ups, that often precede new bone growth. The drug works by blocking activin A, a signaling molecule that was only recently identified as the key driver of abnormal bone formation in FOP. Garetosmab has not yet reached approval, and its safety profile has raised real questions, but the trial data has shifted what researchers think is achievable for a disease that previously had no approved targeted therapy.

Why Activin A Is the Problem in FOP

FOP is caused by a mutation in the gene for a receptor called ACVR1, which normally responds to bone morphogenetic proteins. The most common mutation swaps a single amino acid in the receptor’s structure. For years, researchers assumed this mutation simply made the receptor overactive. The real story turned out to be stranger: the mutation rewires the receptor so that it responds to activin A, a signaling molecule that would ordinarily do nothing to promote bone growth through this receptor. In people without FOP, activin A actually blocks certain bone-forming signals through ACVR1. In people with FOP, activin A does the opposite, switching on the osteogenic machinery and triggering new bone formation in muscles and tendons.

Research in genetically accurate mouse models confirmed that activin A is not just involved in the process but required for it. When activin A was removed from the equation, the abnormal bone formation stopped. Distinct populations of progenitor cells living inside muscles and tendons were found to treat activin A as a signal to start building bone, but only when they carried the FOP-causing mutation.

¹ This discovery fundamentally changed the therapeutic approach: rather than trying to dampen the receptor itself, researchers had a specific ligand they could intercept upstream.

What Garetosmab Is and How It Works

Garetosmab is a fully human monoclonal antibody designed to bind and neutralize activin A before it can reach the mutant ACVR1 receptor. By mopping up circulating activin A, the drug aims to prevent the signal that initiates heterotopic ossification (the formation of bone where bone does not belong). It is administered intravenously. A first-in-human phase 1 study established its pharmacokinetic profile and showed that the drug behaved predictably in healthy volunteers, clearing the way for trials in people with FOP.

The logic behind the drug is clean and specific: if activin A is both necessary and sufficient for driving abnormal bone formation in FOP, then blocking it should halt disease progression. This contrasts with broader approaches that target bone formation pathways more generally, which can carry wider systemic effects.

Results From the Phase 2 LUMINA-1 Trial

The pivotal evidence for garetosmab comes from LUMINA-1, a randomized, double-blind, placebo-controlled phase 2 trial. The trial enrolled adults with FOP and measured heterotopic ossification using whole-body low-dose CT scans and sodium fluoride PET/CT imaging, which can detect active bone-forming lesions.

The headline findings centered on new bone lesions. Post-hoc analysis showed about a 97% relative reduction in new lesion activity and roughly a 90% relative reduction in new heterotopic bone volume in the garetosmab group compared to placebo.³ Only 15% of patients on garetosmab developed new heterotopic bone, compared to about 46% of those on placebo. For context, in a disease where every new bone lesion is permanent and progressively locks joints into immobility, those numbers represent something researchers had not seen before.

The trial also had a crossover design. After the initial 28-week blinded period, placebo patients were switched to garetosmab. None of the patients who crossed over developed new heterotopic bone lesions during the treatment period, compared to about 41% of the same group during their time on placebo.⁴ That within-patient comparison is particularly telling because it controls for individual variation in disease severity.

Where the results were less dramatic was in total lesion activity, a measure that includes both new and pre-existing heterotopic bone. The total lesion activity reduction was about 25%, which did not reach statistical significance. This is not surprising given that garetosmab would not be expected to reverse bone that has already formed, only to prevent new bone from developing. The drug is a preventive tool, not a restorative one.

The Impact on Flare-Ups

FOP flare-ups are inflammatory episodes that cause swelling, pain, and reduced mobility in soft tissues. They often, though not always, precede the formation of new heterotopic bone. Among placebo-treated patients in LUMINA-1, about 71% experienced at least one flare-up, and 59% of those patients went on to develop a new bone lesion. Patients who experienced flare-ups before forming new bone accumulated far more heterotopic bone volume than those who did not flare.⁵

Garetosmab meaningfully reduced flare-up burden. Only about 35% of patients on garetosmab reported flare-ups, compared to 71% on placebo. The total number of patient-reported flare-ups was also sharply lower: 13 in the garetosmab group versus 34 in the placebo group. When flare-ups did occur on garetosmab, they were shorter (a median of about 15 days versus 48 days on placebo) and less severe. No garetosmab-treated patients reported severe swelling or severe loss of movement from flare-ups, while nearly a quarter of placebo-treated patients reported severe pain.⁶ Steroid use, a common rescue measure during flare-ups, was also numerically lower in the treatment group (40% versus about 58%).

This matters beyond symptom relief. Because flare-ups appear to be a gateway to new bone formation, suppressing them may be part of how garetosmab prevents heterotopic ossification in the first place. The investigators who assessed flare-ups independently reported even larger reductions than patients did, with investigator-confirmed flare-ups occurring in only 10% of the garetosmab group versus about 42% on placebo.³

Safety Signals and Open Questions

Blocking a signaling molecule as widely active as activin A was always going to raise safety concerns. Activin A does much more in the body than trigger pathological bone formation in FOP; it plays roles in inflammation, tissue repair, and reproductive biology. The LUMINA-1 trial revealed several side effects that occurred more frequently on garetosmab than on placebo:

Nosebleeds: Epistaxis affected half of garetosmab-treated patients compared to about 17% on placebo.
Eyelash loss: Madarosis (loss of eyelashes) occurred in 30% of treated patients and none on placebo.
Skin infections and acne: A composite of skin and soft-tissue infections including acne was reported in 60% of garetosmab patients versus about 13% on placebo.

These side effects are consistent with disrupting activin A’s role in tissue maintenance and repair.³ None were classified as severe during the blinded portion of the trial, but they underscore that systemic activin A blockade has consequences beyond the target disease.

The most serious event came during the open-label extension, when dosing was suspended after a patient died from an adverse event that was initially thought to be bleeding-related.³ Subsequent investigation suggested the initial attribution was incorrect, and dosing eventually resumed. Still, for a disease affecting a very small population, a single fatal event during a trial casts a long shadow and understandably weighs on both regulators and the patient community.

How Garetosmab Compares to Palovarotene

Palovarotene, a retinoic acid receptor agonist, followed a different path to FOP treatment. Rather than targeting the specific upstream signal that initiates abnormal bone formation, palovarotene works further downstream by trying to block the cartilage-to-bone conversion step. In late 2023, palovarotene became the first drug approved for FOP in certain markets, but its road was bumpy. In its pivotal phase 3 trial, palovarotene did not meet its primary endpoint for reducing new heterotopic bone volume, and nearly all patients experienced retinoid-associated side effects such as dry skin and mucous membrane irritation. More troublingly, premature closure of growth plates was observed in a substantial fraction of skeletally immature patients, limiting its use in children, who are exactly the population most in need of early intervention.

Garetosmab and palovarotene address FOP at fundamentally different points in the disease cascade. Garetosmab intercepts the initiating signal; palovarotene tries to block a downstream step that is harder to isolate from normal skeletal development. In principle, these distinct mechanisms could eventually be combined, and researchers have called for investigating combination approaches. But for now, the two drugs represent different therapeutic philosophies, with garetosmab showing stronger effects on new lesion prevention in its trial and palovarotene having the advantage of being further along in the regulatory process.

Tracking FOP With Advanced Imaging

Measuring whether a drug actually works in FOP requires sophisticated imaging. Conventional CT can show existing heterotopic bone, but it is essentially a snapshot of damage already done. Sodium fluoride PET/CT scans are emerging as a more sensitive tool because they detect active bone formation at the molecular level before a lesion becomes visible on CT.⁷

This imaging modality proved critical to the LUMINA-1 trial. It was used not only to quantify total lesion activity but also to distinguish new bone-forming activity from quiescent old lesions. Research in FOP patients has shown that increased sodium fluoride uptake in muscle tissue during a flare-up can predict exactly where heterotopic bone will later form, making the scan a kind of early warning system.⁸ Separate work confirmed that heterotopic bone can also progress silently, without any flare-up symptoms at all, and that PET/CT is sensitive enough to catch this asymptomatic progression.⁹

For drug development, the ability to detect subclinical disease activity matters enormously. If bone formation can proceed without patients noticing, relying on patient-reported flare-ups as a trial endpoint would undercount disease progression. PET/CT imaging fills that gap and will likely remain the gold standard for measuring treatment effects in future FOP trials.

Activin A Blockade in Other Bone and Muscle Conditions

While garetosmab was developed specifically for FOP, the broader activin signaling pathway has attracted attention in conditions far removed from rare genetic disease. Activin A is not just a rogue signal in people with FOP mutations; it is a normal player in bone remodeling, muscle maintenance, and metabolic regulation. That dual nature is what makes blocking it both powerful and complicated.

In normal bone biology, activin A promotes the formation of osteoclasts, the cells that break down bone tissue. Early research showed that activin A synergizes with the well-known bone-resorption signal RANKL to drive osteoclast development from bone marrow precursors. When activin signaling was blocked using soluble receptors, osteoclast formation was virtually abolished.¹⁰ This insight opened a line of research into whether dampening activin signaling could protect against bone loss in conditions like osteoporosis.

Animal studies have been encouraging. In monkeys, a soluble activin receptor fusion protein increased bone mass through what appeared to be a dual mechanism: building new bone and slowing bone breakdown at the same time.¹¹ In mouse models of osteogenesis imperfecta (brittle bone disease), a similar approach increased trabecular bone volume across all genotypes, and improved cortical bone strength in milder forms of the disease.¹²

Where this research gets particularly interesting is at the intersection of bone and muscle loss, a combination called osteosarcopenia that is common in aging and immobility. In mice with both osteopenia and sarcopenia induced by immobilization, antibodies targeting activin receptors increased muscle mass by about 12% and trabecular bone volume by 44%.¹³ A NASA-funded study went further, testing activin pathway blockade in mice sent to the International Space Station. Treated mice maintained both muscle and bone mass during spaceflight at levels comparable to treated mice on the ground, suggesting the approach could counteract disuse atrophy regardless of whether the cause is bedrest, disease, or microgravity.¹⁴

These broader applications involve related but distinct drugs from garetosmab. Garetosmab specifically neutralizes activin A itself, while many of the bone and muscle studies use soluble decoy receptors that mop up multiple ligands including activin A and myostatin. The distinction matters: casting a wider net catches more targets but carries more potential for off-target effects. Bimagrumab, an activin receptor antibody tested for muscle wasting and metabolic conditions, demonstrated this tradeoff in clinical studies. In women taking bimagrumab, follicle-stimulating hormone levels dropped substantially, an effect that reversed after the drug cleared the body.¹⁵ Reproductive hormone shifts like this illustrate why activin pathway drugs will need careful monitoring as they move toward broader clinical use, even when the primary goal is musculoskeletal.

What Comes Next for FOP Treatment

Garetosmab is currently in further clinical development, with longer-term data still being collected. Several important questions remain unanswered. The phase 2 trial was short and enrolled a small number of patients, which is unavoidable in a disease estimated to affect fewer than one in a million people worldwide. Whether the dramatic reduction in new bone formation holds up over years of continuous treatment, whether stopping the drug leads to rebound disease activity, and how the safety profile evolves with prolonged exposure are all unknowns that can only be resolved with more time and more data.

A systematic review of the FOP treatment pipeline has emphasized the need for long-term safety and efficacy follow-up, along with exploration of gene therapy approaches and combination strategies.¹⁶ Gene therapy, which would aim to correct the ACVR1 mutation itself rather than block its downstream effects, remains largely preclinical. Combination therapy, pairing an upstream blocker like garetosmab with a downstream agent like palovarotene, is conceptually appealing but untested in humans.

For the FOP community, the landscape has shifted meaningfully in a short period. A decade ago, there were no drugs in clinical trials that targeted the molecular cause of the disease. The identification of activin A as the key culprit in 2015 led rapidly to garetosmab’s development, and the LUMINA-1 results have validated the therapeutic strategy. The gap between a validated strategy and a widely available, safe, long-term treatment remains real, but it is a different kind of gap than the one the community faced before anyone understood why the disease happened in the first place.